Business
GSK Exercises Option on OXB LentiVector Patents
GSK Exercises Option on OXB LentiVector Patents.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 6411D Oxford Biomedica PLC 28 October 2015 \n\n \n \n \n \n \n \nGSK Exercises Option on Oxford BioMedica's LentiVector® Technology Patents\n \nOxford, UK - 28 October 2015: Oxford BioMedica plc (\"Oxford BioMedica\" or \"the Group\") (LSE: OXB), a leading gene and cell therapy group, announces that GlaxoSmithKline PLC (GSK) has exercised an option to obtain a non-exclusive licence for two rare orphan disease indications under Oxford BioMedica's LentiVector® platform technology patents. This follows an agreement signed between GSK and the Group in December 2013. \n \nJohn Dawson, Chief Executive Officer of Oxford BioMedica, commented: \"This news further underlines the growing importance and demand for Oxford BioMedica's leading technology and IP. We are pleased that GSK are using our unique lentiviral vector platform and hope they can rapidly advance the development of new treatments that will benefit patients suffering from rare orphan indications for whom current treatment options are limited.\"\n \n \n- Ends -\n \n \n\n\n\n\nFor further information, please contact:\n\n\n \n\n\n\n\n \nOxford BioMedica plc:\nJohn Dawson, Chief Executive Officer\nTim Watts, Chief Financial Officer\n\n\n \nTel: +44 (0)1865 783 000\n\n\n\n\n \nConsilium Strategic Communications\nMary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton\n \n\n\n \n \nTel: +44 (0)20 3709 5700\n\n\n\n\n \nNotes for editors\n \nAbout Oxford BioMedica®\nOxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to col...